Effect of Omega-3 PUFA Supplementation in NAFLD Patients

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 2 to Not applicable
    • Interventions: Omega-3 fatty acid diet supplementation (Dietary Supplement), safflower oil (Dietary Supplement) to Fish oil (Dietary Supplement), Safflower oil (Dietary Supplement)
    v11
  2. Trial status: Active, Not Recruiting to Completedv10
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  4. Primary and study completion dates: Feb 2009 to Jun 2010v8
  5. Re-verified, no change to tracked fieldsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study completion date: Oct 2008 to Feb 2009v6
  2. Trial status: Active, Not Recruiting to Recruitingv5 Show 6 more changesShow less
    • Primary completion date: Feb 2009
    • Study completion date: Oct 2006 to Oct 2008
    • Interventions: Omega-3 fatty acid diet supplementation (Drug) to Omega-3 fatty acid diet supplementation (Dietary Supplement), safflower oil (Dietary Supplement)
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
    • Study arms: 0 to 2
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  4. Primary endpoint revised
    • Secondary endpoints: 4 to 2
    v3
  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether dietary supplementation with omega-3 polyunsaturated fatty acids will decrease the amount of fat in liver.
Trial Details
NCT Number NCT00230113
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Non-Alcoholic Fatty Liver Disease
Related terms Non-alcoholic Fatty Liver Disease
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov